📰 Robert Bissonnette News
Page 2 - Robert Bissonnette News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Robert Bissonnette. Real-time updates on events, politics, business and more.
July 7, 2023
An investigational IL-23R antagonist demonstrated significantly greater efficacy across all doses in patients with moderate to severe psoriasis compared with placebo at week 16 in the FRONTIER 1 study.
July 4, 2023
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from its Phase 2b FRONTIER 1 clinical trial...
May 2, 2023
New phase 2 data from the SCRATCH-AD trial found that ruxolitinib 1.5% showed strong results for rapidly reducing itch in eczema patients, an improvement that continued over 28 days.
May 1, 2023
– Adult patients with atopic dermatitis treated with Opzelura experienced rapid and substantial improvement in itch, which was sustained through Day 28 ... | May 1, 2023
March 28, 2023
The phase 3 study evaluated delgocitinib, an investigational topical pan-JAK inhibitor that inhibits activation of the JAK-STAT pathway and targets key mediators of chronic hand eczema.
March 19, 2023
NEW ORLEANS — Phase 3 trial results found delgocitinib cream to significantly improve patient and clinician-reported outcomes of hand eczema, according to a presenter at the American Academy of Dermatology Annual Meeting.“Chronic hand eczema is one of the most frequent and chronic inflammatory disorders affecting hands,” Robert Bissonnette, MD, MSc, CEO and medical director of
February 9, 2023
New York, NY (PRWEB) February 09, 2023 -- Notalgia paresthetica—a nerve disorder characterized by a persistent itch in the upper back—is a common and
January 12, 2023
- Seven posters will include clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and atopic dermatitis (AD), including data from the successful pediatric maximum usage study
October 13, 2022
- Five posters will highlight clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and for atopic dermatitis in patients as young as two - Dermavant Sciences, a biopharmaceutical
August 24, 2022
- Two posters will highlight clinical data for VTAMA cream on treat-to-target outcomes and quality of life measures - Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing